KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Merck (MRK) EBIAT (2016 - 2025)

Merck (MRK) has disclosed EBIAT for 17 consecutive years, with $3.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, EBIAT fell 21.2% to $3.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $18.3 billion, a 6.6% increase, with the full-year FY2025 number at $18.3 billion, up 6.6% from a year prior.
  • EBIAT was $3.0 billion for Q4 2025 at Merck, down from $5.8 billion in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $5.8 billion in Q3 2025 to a low of -$6.0 billion in Q2 2023.
  • A 5-year average of $3.1 billion and a median of $3.8 billion in 2021 define the central range for EBIAT.
  • Peak YoY movement for EBIAT: crashed 251.5% in 2023, then soared 403.63% in 2024.
  • Merck's EBIAT stood at $3.8 billion in 2021, then decreased by 20.99% to $3.0 billion in 2022, then plummeted by 141.12% to -$1.2 billion in 2023, then skyrocketed by 403.63% to $3.8 billion in 2024, then fell by 21.2% to $3.0 billion in 2025.
  • Per Business Quant, the three most recent readings for MRK's EBIAT are $3.0 billion (Q4 2025), $5.8 billion (Q3 2025), and $4.4 billion (Q2 2025).